BioLineRX
BLRX
29 hedge funds and large institutions have $2.12M invested in BioLineRX in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 3 closing their positions.
106% more call options, than puts
Call options by funds: $451K | Put options by funds: $219K
0% more funds holding
Funds holding: 29 → 29 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
14% less capital invested
Capital invested by funds: $2.46M → $2.12M (-$339K)
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$465K |
| 2 |
PAM
PVG Asset Management
Golden,
Colorado
|
+$95.6K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$62.5K |
| 4 |
JP Morgan Chase
New York
|
+$35.5K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$12.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$382K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$166K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$53.8K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$42.5K |
| 5 |
HF
HRT Financial
New York
|
-$21K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
UBS Group
Zurich,
Switzerland
| $471 | -$13.9K | -224 | -97% |
|
|
TCM
27
Tradewinds Capital Management
Bellingham,
Washington
| $314 | – | – | – |
|
|
SM
28
Sabby Management
Miami Beach,
Florida
| – | -$382K | -5,250 | Closed |
|
|
XT
29
XTX Topco
George Town,
Cayman Islands
| – | -$42.5K | -584 | Closed |
|
|
HF
30
HRT Financial
New York
| – | -$21K | -293 | Closed |
|
31
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$3.03K | -49 | -96% |
|
|
BTI
32
Blue Trust Inc
Alpharetta,
Georgia
| – | +$186 | +3 | New |
|
BLRX Hedge Fund Activity: Q4 2023 in Review
29 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q4 2023, worth a combined $2.12M — down 14% from $2.46M a quarter earlier.
Fund positioning in BLRX was balanced in Q4 2023: 3 funds opened new positions, 3 closed out, 6 added to existing stakes and 10 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $465K. The largest seller was Sabby Management, exiting entirely with an estimated $382K sold.
- 29 institutional investors held BioLineRX (BLRX) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $2.12M of BioLineRX stock for Q4 2023, down 14% quarter-over-quarter.
- 3 funds opened new BioLineRX positions in Q4 2023 and 3 closed out, a net change of 0 holders.
- The largest BioLineRX buyer in Q4 2023 was Morgan Stanley, an estimated $465K added.
- The largest BioLineRX seller in Q4 2023 was Sabby Management, an estimated $382K sold.
Based on aggregated 13F filings for Q4 2023.